- Covovax is 9th vaccine approved in Philippines
- Novavax is applying for emergency use in Europe, Canada
MANILA, Nov. 17 (Reuters) – The Philippines has approved a state of emergency use of a COVID-19 vaccine by Novavax Inc (NVAX.O), the head of the food and drug agency said: on Wednesday the ninth vaccine approved in the Southeast Asian country.
The nanoparticle vaccine, under the brand name Covovax, will be manufactured by Serum Institute of India, and has been approved for use on adults aged 18 and over, the head of the bureau, Rolando Enrique Domingo, to: public briefing.
covovax, die had efficacy of 89.7% in clinical trials, will be administered in two doses met an interval of not less than 21 days, Domingo added.
The Philippines has vaccinated more than a quarter of it’s 110 million population.
At the beginning of this month Novavax received her first emergency use authorization from Indonesia. Novavax also submitted an application for approval of the vaccine in Canada and with the European Medicines Agency.
Reporting by Neil Jerome Morales; Editing by Martin Petty
Our standards: The Thomson Reuters Trust Principles.
Read More: World News
Denial of any Responsibility!
AsumeTech is a News Source that Publishes News from its Editorial Team and the Automatic News Aggregation around the News Media. All the Aggregated Content you find on our site is available freely over the Internet; each piece of Content includes the hyperlink to its Primary Source. We have just arranged that in our platform for Educational Purposes only. All the Copyrights and Trademarks belong to their Rightful Owners and all Materials to their Authors. If you are the Content owner and do not want us to publish your materials on our Website, please get in touch with us by email – [email protected]; we will remove the Content from our Website.